Month: June 2023

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.In accordance with the company announcement dated 7 March 2023, Tryg Forsikring A/S has today published a listing prospectus prepared in connection with the application for admission to trading and official listing on Nasdaq Copenhagen A/S’ regulated market of the NOK 600m Perpetual Restricted Tier 1 Capital Notes (the “NOK Notes”) and the SEK 900m Perpetual Restricted Tier 1 Capital Notes (the “SEK Notes” and together with the NOK Notes, the “Notes”). The Notes were issued on 20 March 2023. The...

Provides option to access capital to support commercial and clinical programs BERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has entered into a $50 million Pre-Paid Advance Agreement (PPA) with Yorkville Advisors Global, LP (Yorkville), a global investment management firm. Simultaneously, the Company and Yorkville also entered into a $5.5 million Promissory Note (Note) with approximately $5.0 million funded at closing. “We are executing an ambitious commercial and product development plan, and the flexibility of this funding vehicle enables us to continue operating in this strategic and opportunistic fashion,” commented Guido Baechler,...

 Valoe Corporation        Inside information 29 June 2023 at 09.55 (Finnish time)                 Valoe Oyj (“Valoe” or “Company”) has received an order from a USA headquartered global consumer electronics company (Customer) for developing Solar Cell Designs and producing specific Customized IBC (Interdigitated Back Contact) Cell prototypes. The development project commences immediately and is estimated to take about five months. The research and development team at Valoe’s Lithuanian factory will be responsible for producing the prototypes. The value of this development phase is about EUR 130,000. The parties aim to continue their cooperation once new Cell Designs are ready. According to the existing plan of the Customer the mass production of the Customized Solar Cells for the Customer’s application at the Valoe factory in Lithuania...

Alstom, Northrail and RIVE Private Investment sign a framework contract for 50 Traxx Universal locomotives including servicesFirst locomotives homologated to run at 160 kilometres per hour in the European corridor (Germany, France, Belgium, Luxembourg, Austria, and Poland) Investment realised by RIVE Private Investment’s transportation fund (RTAIF) Northrail acting as asset manager and lessor for and on behalf of RIVE Private Investment29 June 2023 – Alstom, global leader in smart and sustainable mobility, and Northrail AG have completed a framework contract for 50 multi-system Traxx Universal locomotives with a full-service maintenance package for up to 16 years. The investment was arranged and structured by Northrail for the Paris-based infrastructure investment company RIVE Private Investment (RIVE). Northrail will, on behalf of...

SAMPO PLC                 STOCK EXCHANGE RELEASE         29/06/2023 at 08:30 am Sampo plc’s share buybacks 28/06/2023 On 28/06/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  6,028 41.46 AQEU  32,693 41.40 CEUX  10,315 41.50 TQEX  75,964 41.41 XHELTOTAL 125,000 41.42  *rounded to two decimals                 On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is...

To Nasdaq Copenhagen                                                 29 June 2023         Nykredit Realkredit A/S upgrades full-year guidanceThe Nykredit Group raises its guidance for 2023 and now expects profit after tax for 2023 of DKK 9.75-10.75 billion compared with the previously guided range of DKK 9-10 billion. The first six months were driven by continued business and customer growth across the board, and we recorded growth in bank lending among our largest corporate clients. Further, we recorded highly satisfactory growth in the underlying business, partly driven by higher interest rates. The earnings upgrade is also the result of the continued strong credit quality and resilience of our customers, which has led to a minor reversal of loan impairments. Michael Rasmussen, Group Chief Executive, says: – Our financial performance...

  Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal diseaseSanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030, fueled by an accelerated pace of innovation Intent to start at least 5 innovative Phase 3 vaccine programs by 2025Paris, June 29, 2023. Today Sanofi is hosting a Vaccines Investor Event dedicated to its pipeline with key members of its leadership team. The event will highlight how Sanofi’s strategy is supported by vaccines R&D. Since 2019, reinvesting in key growth drivers and a renewed pipeline has positioned the company well as it moves at speed on the second phase of its Play to Win strategy. Sustained growth in the vaccines business will be driven by core franchises of influenza, meningitis, and pediatric vaccines, with the addition...

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the U.S. Food and Drug Administration (“FDA”) has recently agreed a randomized, double-blind, placebo-controlled, multi-regional phase 3 clinical study of tifcemalimab (product code: TAB004/JS004), an anti-BTLA monoclonal antibody used in combination with toripalimab, an anti-PD-1 monoclonal antibody, as consolidation therapy for patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy may proceed. Junshi Biosciences will officially initiate the phase 3 clinical study in the near future. According...

29 June 2023 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 Listing Rules: GAM announces the sale of its third-party Fund Management Services businesses to Carne Group GAM has entered into definitive agreements to sell its loss-making third-party fund management services businesses in Luxembourg and Switzerland (“FMS Businesses”) to Carne Group (“the Transactions”). The GAM Board believes that the Transactions are in the interests of all stakeholders of GAM and represent the implementation of an important part of the Board’s strategic review. The purchase price, which reflects the reduced assets under management (“AuM”) and loss-making nature of the FMS Businesses, is EUR 2.25 million for the Luxembourg business and CHF 0.5 million for the Swiss business, both subject to adjustment based on revenue run rates at closing. In addition,...

VEON reveals faster local currency revenue and EBITDA growth in first five months at AGM Amsterdam, 29 June 2023 07:00 CEST – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, will report its key financial highlights for the first five months of 2023 (“5M23”) at the annual general meeting of shareholders (“AGM”) being held today. During April and May 2023, VEON Group demonstrated accelerated growth in local currency revenues, achieving a 19.0% year-on-year increase. These results have solidified the strong year-to-date performance. While reported currency revenues for the first five months of 2023 saw a 7.6% decline compared to the previous year, local currency revenues increased by 16.8% year-on-year. Notably, five out of our six countries...